AnGes Inc

Healthcare US AMGXF

0.3602USD
0.00(0%)

Last update at 2026-06-02T20:00:00Z

Day Range

0.340.34

LowHigh

52 Week Range

0.340.36

LowHigh

Fundamentals

Previous Close 0.36
Market Cap142.50M
Volume618
P/E Ratio-
Dividend Yield-%
EBITDA-5091.99974M
Revenue TTM874.00M
Revenue Per Share TTM2.46
Gross Profit TTM 320.00M
Diluted EPS TTM-0.79

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Income before tax	-5236.58300M	-27643.66700M	-7471.41500M	-	-13735.29400M
Minority interest	-	-	-	-	-
Net income	-5123.26900M	-28128.98300M	-7437.60700M	-	-13675.58700M
Selling general administrative	1912.60M	5573.76M	5814.01M	-	4855.70M
Selling and marketing expenses	-	-	-	-	-
Gross profit	320.38M	247.70M	19.45M	-	7.43M
Reconciled depreciation	53.84M	3371.64M	3109.06M	-	2426.08M
Ebit	-	-	-	-16316.00000M	-15632.00000M
Ebitda	-	-	-	-	-13206.00400M
Depreciation and amortization	-	-	-	-	-
Non operating income net other	-	-	-	-	-
Operating income	-5145.39400M	-9109.44500M	-11967.50400M	-	-15632.08500M
Other operating expenses	-	-	-	-	256.00M
Interest expense	-	-	-	-	0.00000M
Tax provision	-113.31400M	485.32M	-33.80700M	-	-59.70600M
Interest income	14.86M	4.45M	8.41M	-	0.57M
Net interest income	-27.48200M	-53.13100M	-11.80400M	-	-97.37300M
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	-	-	-	-2.00000M	-59.00000M
Total revenue	874.12M	643.64M	152.99M	-	64.15M
Total operating expenses	6019.51M	9753.08M	12120.49M	-	15696.23M
Cost of revenue	553.74M	395.94M	133.54M	-	56.72M
Total other income expense net	-	-	-	-	-
Discontinued operations	-	-	-	-	-
Net income from continuing ops	-5123.26900M	-28128.98300M	-7437.60800M	-	-13675.58800M
Net income applicable to common shares	-	-	-	-14714.00000M	-13675.00000M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total assets	5405.98M	4668.60M	28892.54M	38820.71M	45455.75M
Intangible assets	7.63M	9.66M	-	-	-
Earning assets	-	-	-	-	-
Other current assets	28.50M	9.91M	32.60M	361.00M	1786.00M
Total liab	2329.90M	2512.01M	2789.37M	8395.31M	6821.01M
Total stockholder equity	3076.08M	2156.59M	26103.17M	30425.41M	38634.74M
Deferred long term liab	-	-	-	-	-
Other current liab	13.11M	14.18M	15.44M	6520.00M	5933.00M
Common stock	-	-	-	35146.00M	33359.00M
Capital stock	40228.66M	37255.89M	35053.89M	35146.37M	33359.57M
Retained earnings	-51637.86300M	-46514.59400M	-18385.61000M	-27150.00000M	-12435.00000M
Other liab	-	-	-	80.00M	89.00M
Good will	-	0.00000M	21746.09M	23254.47M	22675.74M
Other assets	-	-	-	160.00M	111.00M
Cash	1882.01M	1707.76M	4160.42M	11035.10M	17899.34M
Cash and equivalents	-	-	-	-	-
Total current liabilities	2243.47M	2313.28M	2493.16M	7323.00M	6733.00M
Current deferred revenue	-	-	-	-	-
Net debt	-	-	-	-	-
Short term debt	-	-	-	-	-
Short long term debt	-	-	-	-	-
Short long term debt total	-	-	-	-	-
Other stockholder equity	-	-	-	4960.00M	2029.00M
Property plant equipment	-	-	-	1410.00M	193.00M
Total current assets	4386.54M	3542.61M	5921.28M	12896.00M	21426.00M
Long term investments	-	-	-	-	-
Net tangible assets	-	-	-	7169.00M	15958.00M
Short term investments	-	-	-	-	-
Net receivables	121.62M	85.23M	26.53M	401.00M	429.00M
Long term debt	-	-	-	-	-
Inventory	1746.52M	1429.18M	1566.14M	1008.00M	1223.00M
Accounts payable	542.96M	307.94M	426.45M	553.00M	720.00M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	-	-	-	-	-
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	2.88M	0.95M	1.51M	81.25M	73.48M
Deferred long term asset charges	-	-	-	-	-
Non current assets total	1019.44M	1125.99M	22971.26M	25924.25M	24029.60M
Capital lease obligations	54.37M	272.45M	362.68M	1155.71M	-
Long term debt total	-	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Investments	0.00000M	-56.95000M	-356.65300M	-74.00000M	-74.00000M
Change to liabilities	-	-	-	-317.00000M	-453.00000M
Total cashflows from investing activities	-	-	-	-97.00000M	-154.00000M
Net borrowings	0.00000M	1300.00M	0.00000M	-	-
Total cash from financing activities	-	-	-	3572.00M	17378.00M
Change to operating activities	-	-	-	641.00M	261.00M
Net income	-5123.26900M	-28128.00000M	1067.00M	-14714.00000M	-13675.00000M
Change in cash	168.40M	-2464.49000M	-6877.52300M	-6866.00000M	6298.00M
Begin period cash flow	1627.67M	4092.16M	10969.68M	17835.70M	11537.03M
End period cash flow	1796.07M	1627.67M	4092.16M	-	17835.70M
Total cash from operating activities	-5750.36600M	-6612.87500M	-8745.75900M	-11214.00000M	-11380.00000M
Issuance of capital stock	5870.21M	3008.40M	2033.14M	-	17280.79M
Depreciation	53.84M	3371.64M	3109.06M	2901.00M	2425.00M
Other cashflows from investing activities	-	-	-	-4.00000M	-74.00000M
Dividends paid	-	-	-	-	-
Change to inventory	-317.33300M	136.95M	-557.68700M	215.00M	-32.00000M
Change to account receivables	-	-	-	-	2.00M
Sale purchase of stock	0.00000M	-0.00800M	0.00000M	-	-0.32000M
Other cashflows from financing activities	-	-	-	-	-
Change to netincome	-	-	-	62.00M	152.00M
Capital expenditures	14.32M	77.45M	89.33M	19.00M	80.00M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	-622.52700M	-374.52900M	-5106.12300M	-	194.05M
Stock based compensation	0.35M	5.19M	42.43M	-	60.65M
Other non cash items	22.31M	46.90M	8.71M	-	62.58M
Free cash flow	-5764.68800M	-6690.32700M	-8835.09000M	-	-11478.14200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
AMGXF AnGes Inc	- -%	0.36	-	-	0.16	0.73	38.42	-0.0055
NVO Novo Nordisk A/S	-0.92 2.14%	42.00	41.58	31.15	2.13	32.99	2.11	4.70
NONOF Novo Nordisk A/S	-0.75 1.73%	42.50	41.06	31.25	2.08	33.11	2.11	4.70
VRTX Vertex Pharmaceuticals Inc	3.25 0.76%	428.34	29.67	24.33	10.38	5.83	9.33	20.00
REGN Regeneron Pharmaceuticals Inc	16.03 2.66%	618.95	29.07	20.12	7.57	3.82	6.95	19.42

Reports Covered

View All

Profile

AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.

AnGes Inc

Saito Bio-Incubator, Ibaraki, Japan, 567-0085

81 72 643 3590
https://www.anges.co.jp
Employees : 56

Key Executives

Name	Title	Year Born
Dr. Ei Yamada M.D., Ph.D.	CEO, Pres & Representative Director	1950
Naoya Sato	Director of Corp. Devel. & Director	NA
Dr. Ei Yamada M.D., Ph.D.	CEO, President & Representative Director	1950
Mr. Naoya Sato	Director of Corporate Development & Director	1960
Yuka Murakami	Accounting Department Manager	NA
Mr. Naoya Sato	Director of Administration & Director	1960

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.